Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024)

Century Therapeutics (IPSC) has disclosed Current Deferred Revenue for 3 consecutive years, with $109.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue rose 2396.89% to $109.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $109.2 million, a 2396.89% increase, with the full-year FY2024 number at $109.2 million, up 2396.89% from a year prior.
  • Current Deferred Revenue was $109.2 million for Q4 2024 at Century Therapeutics, up from $3.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $109.2 million in Q4 2024 to a low of $3.6 million in Q3 2024.
  • A 3-year average of $14.4 million and a median of $6.4 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: tumbled 48.87% in 2023, then surged 2396.89% in 2024.
  • Century Therapeutics' Current Deferred Revenue stood at $7.2 million in 2022, then plummeted by 38.89% to $4.4 million in 2023, then soared by 2396.89% to $109.2 million in 2024.
  • Per Business Quant, the three most recent readings for IPSC's Current Deferred Revenue are $109.2 million (Q4 2024), $3.6 million (Q3 2024), and $4.4 million (Q2 2024).